🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to health experts.

An International Public Health Issue

Cases of gonorrhoea are escalating around the world, with data suggesting in excess of 82 million infections each year. Notably increased rates are reported in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs currently available.”

Medical experts are increasingly worried about the rise in drug-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Authorization

One new antibiotic, alternatively called a brand name, was authorized by the American regulatory agency in mid-December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists believe that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, was also approved in close succession. This medication, which is employed against UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to develop it.

“This milestone signifies a major breakthrough in the therapy of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to findings published in a major medical journal, zoliflodacin eradicated more than 90% of uncomplicated infections. This establishes an comparable level with the typical regimen, which involves a dual-drug approach. The trial enrolled nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the ability to register and commercialise the drug in many low-income and middle-income countries.

Clinicians on the front lines have shared hope. Having a single-dose, oral treatment like this is seen as a "revolutionary step" for public health efforts. This is deemed essential to alleviate the strain of the infection for patients and to halt the transmission of untreatable gonorrhoea globally.